Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.57 |
| ▸ | MTNR1A | P48039 | 11/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 11/20 | 0.51 |
| ▸ | NQO2 | P16083 | 1/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7526324 | 0.91 | ALDH1A1 (0.55) | ABCG2MTNR1AMTNR1BNQO2NR4A2 | |
| SCHEMBL4406870 | 0.88 | ABCG2 (0.60) | ABCG2MTNR1AMTNR1BNQO2NR4A2 | |
| SCHEMBL7384942 | 0.87 | ABCG2 (0.56) | ABCG2MTNR1AMTNR1BNQO2NR4A2 | |
| SCHEMBL16312903 | 0.86 | ABCG2 (0.61) | ABCG2MTNR1AMTNR1BNQO2NR4A2 | |
| SCHEMBL7284017 | 0.85 | ABCG2 (0.60) | ABCG2MTNR1AMTNR1BNQO2NR4A2 | |
| SCHEMBL7985067 | 0.84 | NR4A2 (0.64) | ABCG2MTNR1AMTNR1BNQO2NR4A2 | |
| SCHEMBL10840363 | 0.82 | ABCG2 (0.52) | ABCG2MTNR1AMTNR1BNQO2ADRB2 | |
| SCHEMBL29164506 | 0.80 | HTT (0.61) | ABCG2MTNR1AMTNR1BNQO2ADRB2 | |
| SCHEMBL11092490 | 0.80 | ALDH1A1 (0.54) | ABCG2MTNR1AMTNR1BNQO2ADRB2 | |
| SCHEMBL4009106 | 0.79 | ALDH1A1 (0.53) | NR4A2ALDH1A1KDM4EHPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517881-B2 | Triazine derivatives, their preparation and therapeutic application thereof | AVENTIS PHARMA S.A. (FR) | 2009-04-14 | — | — | US | disclosed |
| US-20080096891-A1 | TRIAZINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATION THEREOF | AVENTIS PHARMA S.A. (FR) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096891-A1 | TRIAZINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC APPLICATION THEREOF | CYP11B2, IL5, TBXA2R | ABCG2 417/4885MTNR1A 233/4885MTNR1B 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.